Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05367908 · ClinicalTrials.gov registry record
A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
A clinical trial, sponsored by ModernaTX.
- Completed
- Registry status
- 1,501
- Enrollment target
NCT05367908: Completed study, sponsored by ModernaTX.
NCT05367908 is a clinical trial that has completed, run by ModernaTX. The registered enrollment target is 1,501 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05367908 has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- 1,501 participants
- Enrollment target
Study Summary
This study will investigate antibody levels with respect to time since receiving a COVID-19 booster shot. The study will be decentralized, where participants can complete all study tasks at home. Self-reported participant information will be collected via surveys conducted at intake and monthly throughout the study. Participants will also perform monthly at-home capillary blood draws via YourBio devices that will be mailed to the designated laboratory for sample processing and antibody testing.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,501 participants |
| Start Date | 2022-04-11 |
| Est. Completion | 2022-08-14 |
What the finished NCT05367908 record still lists
NCT05367908 is an observational study that tracks outcomes without assigning an intervention. Its 1,501 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05367908 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05367908 about?
NCT05367908 is a clinical study titled "A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind". This study will investigate antibody levels with respect to time since receiving a COVID-19 booster shot. The study will be decentralized, where participants can complete all study tasks at home. Self-reported participant information will be collected via surveys conducted at intake and monthly thro...
What is the current status of trial NCT05367908?
This trial is currently completed. The enrollment target is 1,501 participants. The study started on 2022-04-11. Estimated completion is 2022-08-14.
Who is sponsoring clinical trial NCT05367908?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI